Illumina and Pillar Biosciences, Inc. Announce Agreement

Pillar Biosciences to Collaborate with Illumina on Next-Generation Sequencing Based In Vitro Diagnostics Development

Illumina and Pillar Biosciences, Inc. Announce Agreement
2017年10月26日

Illumina and Pillar Biosciences, Inc. today announced an agreement to develop next-generation sequencing (NGS) based in vitro diagnostic (IVD) tests. Under the terms of the agreement, Pillar Biosciences will lead the development of a series of diagnostic tests that will be run on the Illumina MiSeq™Dx instrument.

Pillar Biosciences has developed Stem Loop Inhibition Mediated Amplification (SLIMamp®), an innovative technology to maximize the efficiency and performance of targeted NGS panels for the clinical user.

Gang Song, Ph.D., CEO of Pillar Biosciences, stated: “The combination of two state-of the-art NGS technologies, SLIMamp and MiSeqDx, will enable affordable precision medicine and make NGS accessible to clinical laboratories.”

The SLIMamp technology is optimized for highly multiplexed reactions from a single tube with as little as 2.5 ng of DNA, supporting sequencing from FFPE and biofluids. Specifically designed to enable automation, it offers a unique technology that can leverage the power of the MiSeqDx to provide superior uniformity and specificity. SLIMamp based NGS panels provide highly sensitive variant detection in regions of interest including GC-rich regions and low quality samples. Pillar intends to submit multiple NGS assays to the FDA starting in 2018.

Recent Articles

向学生展示STEM职业的无限可能
向学生展示STEM职业的无限可能
卵巢癌幸存者创办非营利组织,帮助年轻患者
卵巢癌幸存者创办非营利组织,帮助年轻患者
国际女性工程师日快乐!
国际女性工程师日快乐!